AML market is growing RAPIDLY! Huge growth at a CAGR of 17.3 % -could $1 Billion+
"..The Acute Myeloid Leukemia (AML) therapeutics market is forecasted to reach USD 731.1 million in 2018. Future AML therapeutics market shows unprecedented growth at a CAGR of 17.3 % from 2011 to 2018 while in the past, growth rate was only 2.9% from 2005 – 2010. The reasons behind the huge growth rate are increase in ageing population, strong products pipeline, high unmet medical needs and entry of quality products. North America accounted for 62% sales of leukemia drugs in the therapeutics market during 2010 followed by Europe and Asia Pacific. AML therapeutics market will grow and the total growth will depend on pipeline products and metabolic inhibitors, a tyrosine kinase receptor FLT -3 of Novartis and some other capable molecules, improving the therapeutics market. Globally the numbers of elderly people, 60 years and above are growing and it is expected that this age group will cross the 1.3 billion mark in 2017. Hence the acute myeloid leukemia therapeutics market will also grow. Many AML products are in the pipeline or in different clinical phases that will bring the change in disease treatment..."